| P2093 | author name string | I Syed | |
| | V S Sunkaraneni | |
| P2860 | cites work | Septectomy and septal dermoplasty for the treatment of severe transfusion-dependent epistaxis in patients with hereditary hemorrhagic telangiectasia and septal perforation. | Q53184790 |
| | Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. | Q59358997 |
| | Hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Management of epistaxis in nine patients using systemic hormone therapy | Q67546823 |
| | Estrogen treatment of hereditary hemorrhagic telangiectasia. A double-blind controlled clinical trial | Q70157588 |
| | Estrogen and progesterone receptors in hereditary hemorrhagic telangiectasia | Q70508070 |
| | Modified Young's procedure for refractory epistaxis due to hereditary hemorrhagic telangiectasia | Q72154854 |
| | Hereditary haemorrhagic telangiectasia: Young's procedure in the management of epistaxis | Q72814418 |
| | Epistaxis in patients with hereditary hemorrhagic telangiectasia treated with selective arterial embolization | Q84686527 |
| | Office-based pulsed dye laser treatment for hemorrhagic telangiectasias and epistaxis | Q30941192 |
| | Plasma surgery and topical estriol: effects on the nasal mucosa and long-term results in patients with Osler's disease | Q30980474 |
| | Argon plasma coagulation for the treatment of hereditary hemorrhagic telangiectasia | Q31920273 |
| | Intranasal tranexamic acid treatment for severe epistaxis in hereditary hemorrhagic telangiectasia | Q32084543 |
| | Treatment of hereditary haemorrhagic telangiectasia by the pulsed dye laser | Q32116087 |
| | The use of a nasal obturator in hereditary haemorrhagic telangiectasia: an alternative to Young's procedure | Q33184890 |
| | Management of epistaxis in hereditary hemorrhagic telangiectasia by Nd:YAG laser and quality of life assessment using the HR-QoL questionnaire | Q33212390 |
| | The effect of treatment for epistaxis secondary to hereditary hemorrhagic telangiectasia. | Q33213303 |
| | The utility of bipolar electrocautery in hereditary hemorrhagic telangiectasia | Q33244952 |
| | The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis | Q33328736 |
| | A retrospective analysis of low dose, intranasal injected bevacizumab (Avastin) in hereditary haemorrhagic telangiectasia | Q33976779 |
| | Coblation for epistaxis management in patients with hereditary haemorrhagic telangiectasia: a multicentre case series. | Q33994212 |
| | International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. | Q34018196 |
| | Bevacizumab in hereditary hemorrhagic telangiectasia-associated epistaxis: effectiveness of an injection protocol based on the vascular anatomy of the nose | Q34260695 |
| | The Young's procedure for severe epistaxis from hereditary hemorrhagic telangiectasia | Q34483680 |
| | Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia. | Q36881940 |
| | Correlation of severity of epistaxis with nasal telangiectasias in hereditary hemorrhagic telangiectasia (HHT) patients | Q37451844 |
| | Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis | Q37846178 |
| | Safety of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis | Q37846182 |
| | Treatment of hereditary hemorrhagic telangiectasia with submucosal and topical bevacizumab therapy | Q37965478 |
| | Endovascular treatment of epistaxis: indications, management, and outcome | Q39267884 |
| | Efficacy of unusually high doses of tranexamic acid for the treatment of epistaxis in hereditary hemorrhagic telangiectasia. | Q43743645 |
| | The treatment of recurrent epistaxis due to hereditary haemorrhagic telangiectasia with intranasal bevacizumab | Q44184208 |
| | Antiestrogen therapy for hereditary hemorrhagic telangiectasia: a double-blind placebo-controlled clinical trial | Q46152895 |
| | Pilot study of submucosal radiofrequency for epistaxis in hereditary hemorrhagic telangiectasia | Q46709801 |
| | Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study | Q48191418 |
| | Argon plasma coagulation is an effective treatment for hereditary hemorrhagic telangiectasia patients with severe nosebleeds | Q48372227 |
| | Local sclerotherapy with polydocanol (Aethoxysklerol®) for the treatment of Epistaxis in Rendu-Osler-Weber or Hereditary Hemorrhagic Telangiectasia (HHT): 15 years of experience | Q48587096 |
| | Anti-estrogen therapy for hereditary hemorrhagic telangiectasia - a long-term clinical trial | Q48632435 |
| | Treatment of epistaxis in hereditary hemorrhagic telangiectasia patients by argon plasma coagulation with local anesthesia | Q48665127 |
| | An epistaxis severity score for hereditary hemorrhagic telangiectasia | Q48906632 |
| | Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: a population based study. | Q52993249 |
| P433 | issue | 5 | |
| P921 | main subject | nosebleed | Q202013 |
| P304 | page(s) | 410-415 | |
| P577 | publication date | 2015-03-04 | |
| P1433 | published in | Journal of Laryngology and Otology | Q13739438 |
| P1476 | title | Evidence-based management of epistaxis in hereditary haemorrhagic telangiectasia | |
| P478 | volume | 129 | |